Earnings Call Summary | Haemonetics(HAE.US) Q4 2024 Earnings Conference
Earnings Call Summary | Haemonetics(HAE.US) Q4 2024 Earnings Conference
The following is a summary of the Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript:
以下是 Haemonetics Corporation (HAE) 2024 年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Haemonetics Corporation saw an organic revenue growth of 10% in Q4 and 12% for the total fiscal 2024 year.
It reported adjusted earnings per diluted share of $0.90 in Q4 and $3.96 for the year, marking an increase of both 17% and 31% respectively.
The company's FY 2024 adjusted gross margin stood at 54.4%, an increase of 1.2% from the previous year.
The adjusted net income for 2024 grew by 31% to $203.6 million. With the same percentage increase, adjusted earnings per share reached to $3.96.
The adjusted income tax for FY '24 settled at 23%.
Haemonetics Corporation在第四季度實現了10％的有機收入增長，2024財年的總收入增長了12％。
該公司報告稱，第四季度調整後的攤薄後每股收益爲0.90美元，該年度的調整後攤薄後每股收益爲3.96美元，分別增長了17％和31％。
該公司2024財年調整後的毛利率爲54.4％，比上年增長1.2％。
2024年調整後的淨收入增長了31％，達到2.036億美元。以同樣的百分比增長，調整後的每股收益達到3.96美元。
24財年的調整後所得稅爲23％。
Business Progress:
業務進展：
Haemonetics restructured its revenue reporting, incorporating services into commercial business units, starting FY 2025.
The company successfully introduced Express Plus in a limited market release, leading to usage in over 60,000 real-world collections.
The company made notable progress in portfolio rationalization, prioritizing focus on global apheresis to improve the margin profile.
The acquisition of OpSens and Attune been announced to boost future growth.
For FY 2025, the company is projecting reported revenue growth to be in the range of 5% to 8%.
It expects gross savings of $15 million from their Operational Excellence Program, benefiting their adjusted operating margins by about $10 million in FY 2025.
Haemonetics is preparing for business expansion opportunities and share buybacks and debt repayment, intending to expand the product portfolio and increase returns.
It plans to accelerate the rollout of Express Plus, the NexSys device upgrade, pledging confidence in the premium innovation.
The company anticipates revenue growth from both plasma and hospital markets, notably due to high-margin products.
Departure of earnings from CSL, 10% of earnings, will gradually impact the margin dynamics linearly.
Market expansion particularly seen in Japan with over 90 accounts and a proactive approach to work through European markets.
從2025財年開始，Haemonetics重組了收入報告，將服務納入商業業務部門。
該公司成功地在限量市場上推出了Express Plus，並已在超過60,000個現實世界中使用。
該公司在投資組合合理化方面取得了顯著進展，將重點放在全球血液分離上，以改善利潤狀況。
宣佈收購OpSens和Attune以促進未來的增長。
對於2025財年，該公司預計報告的收入增長將在5％至8％之間。
該公司預計，其卓越運營計劃將總共節省1500萬美元，使他們在2025財年調整後的營業利潤率增加約1000萬美元。
Haemonetics正在爲業務擴張機會、股票回購和債務償還做準備，打算擴大產品組合並增加回報。
它計劃加快NexSys設備升級版Express Plus的推出，承諾對這項優質創新的信心。
該公司預計，血漿和醫院市場的收入均將增長，這主要是由於高利潤率的產品。
從CSL離職，即收益的10％，將逐漸對利潤率動態產生線性影響。
市場擴張在日本尤其明顯，日本擁有90多個賬戶，並採取積極主動的方法在歐洲市場開展業務。
More details: Haemonetics IR
更多詳情： Haemonetics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。